tracking the risk management results, to find out that they are controlled and managed in the acceptable levels. From the following reasons concluding that the operating results of the Company in the year

, bill payment, and social insurance contributions payment. As a result, the company was able to find new customers. This is consistent with the top up value, which continues to grow consistently

the year 2017, attached please find the Management Discussion and Analysis (MD&A) of the year 2017. This report should be considered in conjunction with the submitted financial statements in which the

find out that they are controlled and managed in the acceptable levels. From the following reasons concluding that the operating results of the Company of year 2017 decreased comparing to last year. For

, please kindly find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period ended 31 December 2017 MANAGEMENT DISCUSSION AND

find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period ended 31 March 2019 MANAGEMENT DISCUSSION AND ANALYSIS Golden

the Company and its shareholders. Due to the biopharmaceuticals products for eliminate the water hyacinth are the new innovative products that has passed the researched and testing until find that can

the Company and its subsidiary, please kindly find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period ended 31 March

results of the Company and its subsidiary, please kindly find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period ended 30

operating results of the Company and its subsidiary, please kindly find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period